Meeting
2023 ASCO Annual Meeting
Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).
Authors
Mouna Bidaraguppe B M
New Delhi, India
Mouna Bidaraguppe B M , akash kumar , Atul Batra , Vinod Sharma , Babita Kataria , Ajay Gogia , Sandeep Mathur , Aparna Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
REF/2022/05/054208
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS631)
DOI
10.1200/JCO.2023.41.16_suppl.TPS631
Abstract #
TPS631
Poster Bd #
453a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Factors predicting pathological complete response in patients with localized breast cancer receiving neoadjuvant chemotherapy.
First Author: Arya Mariam Roy
Poster
2023 ASCO Annual Meeting
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
First Author: Kun Wang
Poster
2023 ASCO Annual Meeting
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
First Author: Jai Min Ryu
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy